Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Akouos, Inc. AKUS
$13.29
На 18:02, 12 мая 2023
-2.18%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
13.60
-
week52low
2.32
-
Revenue
0
-
P/E TTM
-5
-
Beta
-0.56132500
-
EPS
-2.83200000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 ноя 2022 г. в 01:37
Описание компании
Akouos, Inc., a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 18 мая 2022 г. |
| HC Wainwright & Co. | Buy | 27 апр 2021 г. | |
| B of A Securities | Neutral | Buy | 30 мар 2021 г. |
| Piper Sandler | Overweight | Overweight | 21 июл 2020 г. |
| Cowen & Co. | Outperform | Outperform | 21 июл 2020 г. |
| William Blair | Outperform | 29 сент 2022 г. | |
| William Blair | Market Perform | Outperform | 19 окт 2022 г. |
| Piper Sandler | Neutral | Overweight | 19 окт 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 18 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Mathers Edward T | D | 0 | 16000 | 01 дек 2022 г. |
| Simons Emmanuel | D | 0 | 380000 | 01 дек 2022 г. |
| TZIANABOS ARTHUR | D | 0 | 16000 | 01 дек 2022 г. |
| Wellman Jennifer Anne | D | 0 | 130000 | 01 дек 2022 г. |
| McKenna Michael John | D | 0 | 90000 | 01 дек 2022 г. |
| Minegishi Sachiyo | D | 0 | 150000 | 01 дек 2022 г. |
| PARMAR KUSH | D | 0 | 16000 | 01 дек 2022 г. |
| Preston Heather | D | 0 | 16000 | 01 дек 2022 г. |
| Ramasastry Saira | D | 0 | 16000 | 01 дек 2022 г. |
| SATO VICKI L | D | 0 | 16000 | 01 дек 2022 г. |
Новостная лента
Why Is Akouos (AKUS) Stock Up 85% Today?
InvestorPlace
18 окт 2022 г. в 10:46
There's notable merger news today as pharmaceutical giant Eli Lilly (NYSE: LLY ) entered into a definitive agreement to acquire Akouos (NASDAQ: AKUS ). Clearly, Eli Lilly is looking to expand further into gene therapies.
Why Akouos Stock Is on Fire Today
The Motley Fool
18 окт 2022 г. в 09:37
A buyout agreement is lighting a fire underneath the biotech's shares today.
Eli Lilly to buy genetic medicine developer Akouos for $487 million
Reuters
18 окт 2022 г. в 07:05
Drugmaker Eli Lilly and Co will acquire genetic medicine developer Akouos Inc in a cash deal worth about $487 million.
Eli Lilly to acquire Akouos for up to about $610 million and develop gene therapies for hearing loss
Market Watch
18 окт 2022 г. в 07:01
Eli Lilly and Co. LLY, +0.41% said Tuesday it has entered an agreement to acquire Akouos Inc. AKUS, -5.14% , a company developing a portfolio of viral gene therapies for the treatment of inner ear conditions including hearing loss, for up to $610 million in cash. Under the terms of the deal, Akouos shareholders will receive $12.50 a share in cash, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 in cash, for a total consideration of up to $15.50 per share in cash without interest, or an aggregate of $610 million.
Akouos, Inc. (AKUS) Upgraded to Strong Buy: Here's Why
Zacks Investment Research
10 окт 2022 г. в 13:32
Akouos, Inc. (AKUS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.